FibroBiologics(NASDAQ) FBLG

Market Cap$4.26M

Since IPO (2024)-100%

5 YearN/A

1 Year-95%

1 Month-23%

$0.70

-3.27%

-0.02Today

FibroBiologics last closing stock price
Metric	Price	Date
Last close	USD 0.70	2026-07-31

FibroBiologics stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-1.69%	USD 0.71	2026-07-24
1 month	-22.76%	USD 0.91	2026-07-01
3 month	-52.05%	USD 1.46	2026-05-01
Year to date	-84.44%	USD 4.50	2025-12-31
1 year	-94.51%	USD 12.74	2025-07-31
Since inception	-99.88%	USD 582.00	2024-01-31

FibroBiologics Financials at a Glance

Market Cap

$4.26M

Revenue (TTM)

$0.00

Net Income (TTM)

-$18.14M

EPS (TTM)

-$5.64

P/E Ratio

-0.09

Dividend

$0.00

Beta (Volatility)

-0.04 (Low)

Dividend

$0.00

Beta (Volatility)

-0.04 (Low)

Price

$0.70

Volume

111,549.401

Open

$0.74

Price

$0.70

Volume

111,549.401

Open

$0.74

Previous Close

$0.70

Daily Range

$0.68 - $0.74

52-Week Range

$0.62 - $13.00

Estimated Earnings Date

Oct 30, 2026

Dividend

$0.00

Beta (Volatility)

-0.04 (Low)

Price

$0.70

Volume

111,549.401

Open

$0.74

Previous Close

$0.70

Daily Range

$0.68 - $0.74

52-Week Range

$0.62 - $13.00

Estimated Earnings Date

Oct 30, 2026

FBLG News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About FibroBiologics

FibroBiologics, Inc., a clinical-stage cell therapy company, specializes in developing and commercializing fibroblast-based therapies for chronic diseases with unmet medical needs. Founded in 2021, it focuses on conditions like degenerative disc disease, multiple sclerosis, and wound healing, using fibroblasts—a cell type advantageous over stem cells due to easier cultivation and superior therapeutic properties.

Products and Services

CybroCell™ for the treatment of degenerative disc disease.

CYMS101 for treating multiple sclerosis.

CYWC628, a therapy for wound healing.

Research on treatment options for psoriasis and cancer.

Early-stage exploration of CYTER915 for life extension applications.

What Makes FibroBiologics, Inc. Special

FibroBiologics, Inc. distinguishes itself with its focus on fibroblast cells, which are more abundant and easier to culture than stem cells. Their therapies are aimed at leveraging these cells' innate regenerative and immune-modulatory capabilities, offering a potentially more cost-effective and scalable therapeutic platform.

Five Things You Need to Know

Fibroblast cells can regenerate tissue and organs, similar to stem cells but are easier to harvest and culture.

The company's pipeline includes several targeted therapies with potential applications in multiple therapeutic areas.

FibroBiologics holds an extensive patent portfolio to protect its innovative fibroblast technology.

The leadership team comprises experienced professionals in cell-based therapies and life sciences.

FibroBiologics plans to build a manufacturing facility to streamline production for clinical trials and future sales.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Peter O'Heeron

Website

www.fibrobiologics.com

Headquarters

Houston, TX 77598, US

FBLG Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-536.78%

Return on Capital

-194.36%

Return on Assets

-228.77%

Earnings Yield

-11.11%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$4.26M

Shares Outstanding

6.08M

Volume

111.55K

Avg. Volume

212.74K

Financials (TTM)

Gross Profit

-$234.00K

Operating Income

-$16.73M

EBITDA

-$17.15M

Operating Cash Flow

-$14.79M

Capital Expenditure

-$6.00K

Free Cash Flow

-$14.80M

Cash & ST Invst.

$3.52M

Total Debt

$1.34M

FibroBiologics Performance Analysis

FibroBiologics annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 0	N/A
2023	2023-12-31	USD 0	N/A
2024	2024-12-31	USD 0	N/A
2025	2025-12-31	USD 0	N/A

FibroBiologics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	N/A
Q4	2025-12-31	N/A
Q1	2026-03-31	N/A
Q2	2026-06-30	N/A

FibroBiologics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -3.15	223.7%
2023	2023-12-31	USD -13.50	328.3%
2024	2024-12-31	USD -6.79	-49.7%
2025	2025-12-31	USD -8.35	23.0%

FibroBiologics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	-8.3%
Q4	2025-12-31	62.3%
Q1	2026-03-31	-128.6%
Q2	2026-06-30	70.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$4.26M

N/A

Market Cap/Employee

$283.76K

N/A

Employees

N/A

Net Income

-$4.12M

+11.6%

EBITDA

-$4.03M

+9.4%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

$3.52M

-60.3%

Total Debt

$1.34M

-87.6%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$1.08M

-48.2%

Short Term Debt

$258.00K

-97.0%

Return on Assets

-2.29%

N/A

Return on Invested Capital

-2.93%

N/A

Free Cash Flow

-$3.29M

+21.6%

Operating Cash Flow

-$3.29M

+17.4%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

AIMDAinos, Inc.

AIMDAinos, Inc.$1.33-2.21%

CTXRCitius Pharmaceuticals, Inc.

CTXRCitius Pharmaceuticals, Inc.$0.57-9.81%

MBRXMoleculin Biotech, Inc.

MBRXMoleculin Biotech, Inc.$0.40-60.78%

ICUSeaStar Medical Holding Corporation

ICUSeaStar Medical Holding Corporation$3.13-1.57%

HOTHHoth Therapeutics, Inc.

HOTHHoth Therapeutics, Inc.$0.79+0.16%

DAREDare Bioscience, Inc.

DAREDare Bioscience, Inc.$1.22-1.61%

APLMApollomics, Inc.

APLMApollomics, Inc.$17.25-0.61%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NVDANvidia

NVDANvidia$200.75+0.03%

AAPLApple

AAPLApple$308.91-0.07%

AMZNAmazon

AMZNAmazon$271.58+0.15%

INTCIntel

INTCIntel$90.20-0.01%

FCUVFocus Universal

FCUVFocus Universal$11.60+5.17%

NOKNokia

NOKNokia$9.14+0.01%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$64.62+0.02%

Questions About FBLG

What is the current price of FibroBiologics?

FibroBiologics is trading at $0.70 per share.

What is the 52-week range for FibroBiologics?

Over the past 52 weeks, FibroBiologics has traded between $0.62 and $13.00.

How much debt does FibroBiologics have?

As of the most recent reporting period, FibroBiologics reported total debt of $1.46M.

How much cash does FibroBiologics have on hand?

FibroBiologics reported $3.52M in cash and cash equivalents in its most recent financial results.

What is FibroBiologics’s dividend yield?

FibroBiologics does not currently have a dividend yield.

FibroBiologics(NASDAQ) FBLG

FibroBiologics Financials at a Glance

FBLG News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About FibroBiologics

Products and Services

What Makes FibroBiologics, Inc. Special

Five Things You Need to Know

FBLG Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

FibroBiologics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About FBLG

What is the current price of FibroBiologics?

What is the 52-week range for FibroBiologics?

How much debt does FibroBiologics have?

How much cash does FibroBiologics have on hand?

What is FibroBiologics’s dividend yield?

Premium Investing Services